How Manufacturers Can Strengthen RWE Submissions for Optimal Use in Regulatory and Reimbursement Decision Making
Dr. Nicole Mittmann
Chief Scientist and Vice President, Scientific Evidence, Methodologies and Resources
CADTH
David Shum
Director, Strategic Access and Pricing
Roche
Brad Millson
General Manager
Real World Solutions
IQVIA
- Identifying acceptable sources of real-world data
- Examining how regulators and HTA bodies are using RWE in decision-making about the safety and efficacy of drugs
- Aligning RWE submissions with HTA expectations
- Understanding how RWE is being assessed
- Determining what is considered a sufficient level or proof or value proposition for recommendations
- Applying RWE reporting best practices to expedite reviews and maximize relevance of submissions
- Understanding how RWE is being assessed